http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 20 Oct 2026 08:33:23 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Vistagen+taps+GATC+Health%27s+AI+platform+for+drug+development+programs/27207281.html <p>Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company, announced a collaboration with GATC Health to apply predictive artificial intelligence to several of its drug development programs, according to a company press release dated Oct. 20, 2026.</p><p>Under the agreement, GATC Health will deploy its Operon® platform and Derisq® predictive intelligence tools to support Vistagen's potential next Phase 3 study of fasedienol for social anxiety disorder, as well as potential Phase 2 studies of itruvone for major depressive disorder and refisolone for menopausal hot flashes.</p><p>The collaboration is intended to provide additional insights for protocol development, pipeline prioritization, and resource allocation by combining http://www.streetinsider.com/Corporate+News/Vistagen+taps+GATC+Health%27s+AI+platform+for+drug+development+programs/27207281.html Tue, 20 Oct 2026 08:33:23 -0400 VTGN http://www.streetinsider.com/Press+Releases/Vistagen+Selects+GATC+Health+to+Apply+Predictive+AI+Across+Lead+Clinical-Stage+Drug+Development+Programs/27207166.html <p><strong>Collaboration combines Vistagen’s neuroscience expertise and datasets with GATC Health’s predictive modeling capabilities to provide additional insights for protocol development and resource allocation</strong></p><p>SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN) a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry, today announced its collaboration with GATC Health, a tech-bio company applying artificial intelligence and multiomics to drug discovery and development. The collaboration brings GATC Health’s proprietary Operon^® platform and Derisq^® report to Vistagen’s lead clinical-stage programs.</p> <p>Through the collaboration, GATC Health uses its Operon^® platform and Derisq^® predictive intelligence capabilities to provide http://www.streetinsider.com/Press+Releases/Vistagen+Selects+GATC+Health+to+Apply+Predictive+AI+Across+Lead+Clinical-Stage+Drug+Development+Programs/27207166.html Tue, 20 Oct 2026 08:30:00 -0400 VTGN http://www.streetinsider.com/Globe+Newswire/Vistagen+Selects+GATC+Health+to+Apply+Predictive+AI+Across+Lead+Clinical-Stage+Drug+Development+Programs/27207166.html <p><strong>Collaboration combines Vistagen’s neuroscience expertise and datasets with GATC Health’s predictive modeling capabilities to provide additional insights for protocol development and resource allocation</strong></p><p>SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN) a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry, today announced its collaboration with GATC Health, a tech-bio company applying artificial intelligence and multiomics to drug discovery and development. The collaboration brings GATC Health’s proprietary Operon^® platform and Derisq^® report to Vistagen’s lead clinical-stage programs.</p> <p>Through the collaboration, GATC Health uses its Operon^® platform and Derisq^® predictive intelligence capabilities to provide http://www.streetinsider.com/Globe+Newswire/Vistagen+Selects+GATC+Health+to+Apply+Predictive+AI+Across+Lead+Clinical-Stage+Drug+Development+Programs/27207166.html Tue, 20 Oct 2026 08:30:00 -0400 VTGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Oct+07/27172306.html si-local-file:///var/storage/secattach/20261009/27172306.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Oct+07/27172306.html Fri, 09 Oct 2026 17:16:00 -0400 VTGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Sep+25/27104599.html si-local-file:///var/storage/secattach/20260925/27104599.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Sep+25/27104599.html Fri, 25 Sep 2026 09:11:00 -0400 VTGN http://www.streetinsider.com/Press+Releases/SRX+Global+Provides+Shareholders+with+Update+on+Liquidation+of+Two+Portfolio+Investments+and+Adds+an+Investment+in+Onconetix+%28Nasdaq%3A+ONCO%29/27101104.html <p><strong>SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras.</strong></p><p>NORTH PALM BEACH, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced an update to shareholders on the liquidation of portfolio holdings Vistagen Therapeutics (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, and Greenland Mines (Nasdaq: http://www.streetinsider.com/Press+Releases/SRX+Global+Provides+Shareholders+with+Update+on+Liquidation+of+Two+Portfolio+Investments+and+Adds+an+Investment+in+Onconetix+%28Nasdaq%3A+ONCO%29/27101104.html Thu, 24 Sep 2026 12:30:00 -0400 GRML ONCO VTGN http://www.streetinsider.com/Globe+Newswire/SRX+Global+Provides+Shareholders+with+Update+on+Liquidation+of+Two+Portfolio+Investments+and+Adds+an+Investment+in+Onconetix+%28Nasdaq%3A+ONCO%29/27101104.html <p><strong>SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras.</strong></p><p>NORTH PALM BEACH, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced an update to shareholders on the liquidation of portfolio holdings Vistagen Therapeutics (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, and Greenland Mines (Nasdaq: http://www.streetinsider.com/Globe+Newswire/SRX+Global+Provides+Shareholders+with+Update+on+Liquidation+of+Two+Portfolio+Investments+and+Adds+an+Investment+in+Onconetix+%28Nasdaq%3A+ONCO%29/27101104.html Thu, 24 Sep 2026 12:30:00 -0400 GRML ONCO VTGN http://www.streetinsider.com/Press+Releases/SRX+Global+Provides+Shareholders+with+Update+on+Liquidation+of+Two+Portfolio+Investments+and+Adds+an+Investment+in+Onconetix+%28Nasdaq%3A+ONCO%29/27101104.html <p><strong>SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras.</strong></p><p>NORTH PALM BEACH, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced an update to shareholders on the liquidation of portfolio holdings Vistagen Therapeutics (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, and Greenland Mines (Nasdaq: http://www.streetinsider.com/Press+Releases/SRX+Global+Provides+Shareholders+with+Update+on+Liquidation+of+Two+Portfolio+Investments+and+Adds+an+Investment+in+Onconetix+%28Nasdaq%3A+ONCO%29/27101104.html Thu, 24 Sep 2026 12:30:00 -0400 GRML ONCO VTGN http://www.streetinsider.com/Globe+Newswire/SRX+Global+Provides+Shareholders+with+Update+on+Liquidation+of+Two+Portfolio+Investments+and+Adds+an+Investment+in+Onconetix+%28Nasdaq%3A+ONCO%29/27101104.html <p><strong>SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras.</strong></p><p>NORTH PALM BEACH, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced an update to shareholders on the liquidation of portfolio holdings Vistagen Therapeutics (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, and Greenland Mines (Nasdaq: http://www.streetinsider.com/Globe+Newswire/SRX+Global+Provides+Shareholders+with+Update+on+Liquidation+of+Two+Portfolio+Investments+and+Adds+an+Investment+in+Onconetix+%28Nasdaq%3A+ONCO%29/27101104.html Thu, 24 Sep 2026 12:30:00 -0400 GRML ONCO VTGN http://www.streetinsider.com/Press+Releases/SRX+Global+Provides+Shareholders+with+Update+on+Liquidation+of+Two+Portfolio+Investments+and+Adds+an+Investment+in+Onconetix+%28Nasdaq%3A+ONCO%29/27101104.html <p><strong>SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras.</strong></p><p>NORTH PALM BEACH, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced an update to shareholders on the liquidation of portfolio holdings Vistagen Therapeutics (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, and Greenland Mines (Nasdaq: http://www.streetinsider.com/Press+Releases/SRX+Global+Provides+Shareholders+with+Update+on+Liquidation+of+Two+Portfolio+Investments+and+Adds+an+Investment+in+Onconetix+%28Nasdaq%3A+ONCO%29/27101104.html Thu, 24 Sep 2026 12:30:00 -0400 GRML ONCO VTGN http://www.streetinsider.com/Globe+Newswire/SRX+Global+Provides+Shareholders+with+Update+on+Liquidation+of+Two+Portfolio+Investments+and+Adds+an+Investment+in+Onconetix+%28Nasdaq%3A+ONCO%29/27101104.html <p><strong>SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras.</strong></p><p>NORTH PALM BEACH, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced an update to shareholders on the liquidation of portfolio holdings Vistagen Therapeutics (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, and Greenland Mines (Nasdaq: http://www.streetinsider.com/Globe+Newswire/SRX+Global+Provides+Shareholders+with+Update+on+Liquidation+of+Two+Portfolio+Investments+and+Adds+an+Investment+in+Onconetix+%28Nasdaq%3A+ONCO%29/27101104.html Thu, 24 Sep 2026 12:30:00 -0400 GRML ONCO VTGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Sep+24/27098765.html si-local-file:///var/storage/secattach/20260924/27098765.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Sep+24/27098765.html Thu, 24 Sep 2026 07:05:00 -0400 VTGN http://www.streetinsider.com/Corporate+News/Vistagen+presents+fasedienol+data+for+severe+social+anxiety+at+congress/27098734.html <p>Vistagen (NASDAQ: VTGN) presented exploratory data at Psych Congress 2026 in New Orleans on Sept. 24, showing potential efficacy signals for its fasedienol nasal spray in participants with very severe social anxiety disorder.</p><p>The data came from subpopulation analyses — one post-hoc and one prespecified — drawn from two randomized, double-blind, placebo-controlled clinical trials. Participants were defined as having very severe social anxiety disorder based on a baseline Liebowitz Social Anxiety Scale score of 95 or higher.</p><p>In the post-hoc analysis from the PALISADE-4 Phase 3 trial, fasedienol showed a statistically significant benefit on average Subjective Units of Distress Scale scores during http://www.streetinsider.com/Corporate+News/Vistagen+presents+fasedienol+data+for+severe+social+anxiety+at+congress/27098734.html Thu, 24 Sep 2026 07:02:17 -0400 VTGN http://www.streetinsider.com/FDA/Vistagen+presents+fasedienol+data+for+severe+social+anxiety+at+congress/27098734.html <p>Vistagen (NASDAQ: VTGN) presented exploratory data at Psych Congress 2026 in New Orleans on Sept. 24, showing potential efficacy signals for its fasedienol nasal spray in participants with very severe social anxiety disorder.</p><p>The data came from subpopulation analyses — one post-hoc and one prespecified — drawn from two randomized, double-blind, placebo-controlled clinical trials. Participants were defined as having very severe social anxiety disorder based on a baseline Liebowitz Social Anxiety Scale score of 95 or higher.</p><p>In the post-hoc analysis from the PALISADE-4 Phase 3 trial, fasedienol showed a statistically significant benefit on average Subjective Units of Distress Scale scores during http://www.streetinsider.com/FDA/Vistagen+presents+fasedienol+data+for+severe+social+anxiety+at+congress/27098734.html Thu, 24 Sep 2026 07:02:17 -0400 VTGN http://www.streetinsider.com/Hot+Corp.+News/Vistagen+presents+fasedienol+data+for+severe+social+anxiety+at+congress/27098734.html <p>Vistagen (NASDAQ: VTGN) presented exploratory data at Psych Congress 2026 in New Orleans on Sept. 24, showing potential efficacy signals for its fasedienol nasal spray in participants with very severe social anxiety disorder.</p><p>The data came from subpopulation analyses — one post-hoc and one prespecified — drawn from two randomized, double-blind, placebo-controlled clinical trials. Participants were defined as having very severe social anxiety disorder based on a baseline Liebowitz Social Anxiety Scale score of 95 or higher.</p><p>In the post-hoc analysis from the PALISADE-4 Phase 3 trial, fasedienol showed a statistically significant benefit on average Subjective Units of Distress Scale scores during http://www.streetinsider.com/Hot+Corp.+News/Vistagen+presents+fasedienol+data+for+severe+social+anxiety+at+congress/27098734.html Thu, 24 Sep 2026 07:02:17 -0400 VTGN http://www.streetinsider.com/Press+Releases/Vistagen+Reports+Positive+Findings+Supporting+Fasedienol%E2%80%99s+Potential+in+Very+Severe+Social+Anxiety+Disorder/27098654.html <p align="center"><em>Exploratory research results presented at Psych Congress 2026 in New Orleans</em></p> <p align="center"><em>Full poster presentation can be found on “Publications” section of Company’s website </em></p> <p>SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented positive exploratory data at Psych Congress 2026 in New Orleans. The poster highlights a potential efficacy signal for fasedienol nasal spray, the Company's rapid-onset Phase 3 product candidate, observed in a public speaking challenge study http://www.streetinsider.com/Press+Releases/Vistagen+Reports+Positive+Findings+Supporting+Fasedienol%E2%80%99s+Potential+in+Very+Severe+Social+Anxiety+Disorder/27098654.html Thu, 24 Sep 2026 07:00:00 -0400 VTGN http://www.streetinsider.com/Globe+Newswire/Vistagen+Reports+Positive+Findings+Supporting+Fasedienol%E2%80%99s+Potential+in+Very+Severe+Social+Anxiety+Disorder/27098654.html <p align="center"><em>Exploratory research results presented at Psych Congress 2026 in New Orleans</em></p> <p align="center"><em>Full poster presentation can be found on “Publications” section of Company’s website </em></p> <p>SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented positive exploratory data at Psych Congress 2026 in New Orleans. The poster highlights a potential efficacy signal for fasedienol nasal spray, the Company's rapid-onset Phase 3 product candidate, observed in a public speaking challenge study http://www.streetinsider.com/Globe+Newswire/Vistagen+Reports+Positive+Findings+Supporting+Fasedienol%E2%80%99s+Potential+in+Very+Severe+Social+Anxiety+Disorder/27098654.html Thu, 24 Sep 2026 07:00:00 -0400 VTGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Sep+22/27091336.html si-local-file:///var/storage/secattach/20260922/27091336.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Sep+22/27091336.html Tue, 22 Sep 2026 16:22:00 -0400 VTGN http://www.streetinsider.com/FDA/Vistagen+reports+safety+and+efficacy+data+from+fasedienol+OLE+study/27088158.html <p>Vistagen (Nasdaq: VTGN) released preliminary data from the open-label extension (OLE) portion of its PALISADE-4 Phase 3 study of fasedienol nasal spray for the acute treatment of social anxiety disorder, according to a company statement dated Sept. 22, 2026.</p> <p>The OLE safety population included 322 adults who used 3.2 µg of fasedienol as needed, up to six times per day, for up to 12 months. The discontinuation rate due to adverse events was 1.6%, with no discontinuations attributed to fasedienol. More than 95% of treatment-emergent adverse events were mild or moderate. The most common adverse events occurring in more than 5% http://www.streetinsider.com/FDA/Vistagen+reports+safety+and+efficacy+data+from+fasedienol+OLE+study/27088158.html Tue, 22 Sep 2026 08:30:15 -0400 VTGN http://www.streetinsider.com/Press+Releases/Vistagen+Announces+Preliminary+Positive+Data+from+Open-Label+Extension+Portion+of+PALISADE-4+Phase+3+Study+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/27088115.html <p align="center"><em>Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months </em></p> <p align="center"><em> Clinically relevant improvement in social anxiety over time was observed on both clinician-administered and patient-reported scales over four months</em></p> <p align="center"><em>PALISADE-4 OLE data add to growing body of evidence supporting fasedienol’s potential to address social anxiety disorder in anxiety-provoking social and performance situations in everyday life</em></p> <p>SOUTH SAN FRANCISCO, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry http://www.streetinsider.com/Press+Releases/Vistagen+Announces+Preliminary+Positive+Data+from+Open-Label+Extension+Portion+of+PALISADE-4+Phase+3+Study+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/27088115.html Tue, 22 Sep 2026 08:30:00 -0400 VTGN http://www.streetinsider.com/Globe+Newswire/Vistagen+Announces+Preliminary+Positive+Data+from+Open-Label+Extension+Portion+of+PALISADE-4+Phase+3+Study+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/27088115.html <p align="center"><em>Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months </em></p> <p align="center"><em> Clinically relevant improvement in social anxiety over time was observed on both clinician-administered and patient-reported scales over four months</em></p> <p align="center"><em>PALISADE-4 OLE data add to growing body of evidence supporting fasedienol’s potential to address social anxiety disorder in anxiety-provoking social and performance situations in everyday life</em></p> <p>SOUTH SAN FRANCISCO, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry http://www.streetinsider.com/Globe+Newswire/Vistagen+Announces+Preliminary+Positive+Data+from+Open-Label+Extension+Portion+of+PALISADE-4+Phase+3+Study+of+Fasedienol+for+the+Acute+Treatment+of+Social+Anxiety+Disorder/27088115.html Tue, 22 Sep 2026 08:30:00 -0400 VTGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Sep+10/27050356.html si-local-file:///var/storage/secattach/20260911/27050356.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vistagen+Therapeutics%2C++++For%3A+Sep+10/27050356.html Fri, 11 Sep 2026 06:02:00 -0400 VTGN http://www.streetinsider.com/Press+Releases/Vistagen+to+Present+at+Psych+Congress+2026/27045628.html <p><strong>Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder</strong></p><p>SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data highlighting a positive efficacy signal for its Phase 3 product candidate, fasedienol nasal spray, in public speaking challenge study participants with very severe social anxiety disorder at Psych Congress in New Orleans on Thursday, September 17, and Friday, September 18, http://www.streetinsider.com/Press+Releases/Vistagen+to+Present+at+Psych+Congress+2026/27045628.html Thu, 10 Sep 2026 08:30:00 -0400 VTGN http://www.streetinsider.com/Globe+Newswire/Vistagen+to+Present+at+Psych+Congress+2026/27045628.html <p><strong>Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder</strong></p><p>SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data highlighting a positive efficacy signal for its Phase 3 product candidate, fasedienol nasal spray, in public speaking challenge study participants with very severe social anxiety disorder at Psych Congress in New Orleans on Thursday, September 17, and Friday, September 18, http://www.streetinsider.com/Globe+Newswire/Vistagen+to+Present+at+Psych+Congress+2026/27045628.html Thu, 10 Sep 2026 08:30:00 -0400 VTGN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vistagen+Therapeutics%2C+++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26933045.html si-local-file:///var/storage/secattach/20260814/26933045.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vistagen+Therapeutics%2C+++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26933045.html Fri, 14 Aug 2026 17:52:00 -0400 O.07328903 VTGN